Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Carcinoma, Renal Cell 6Prostatic Neoplasms 4Rectal Neoplasms 2Melanoma 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Breast Neoplasms 2Brain Neoplasms 2Pancreatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasms 1Kidney Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Fallopian Tube Mucinous Adenocarcinoma 1Ependymoma 1Astrocytoma 1Advanced Prostate Adenocarcinoma 1

Interventions

X-Rays 6Phantoms, Imaging 6Magnetic Resonance Spectroscopy 6Specimen Handling 5Nuclear Medicine Department, Hospital 5Biopsy 4ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2erdafitinib 2ensartinib 2Vemurafenib 2LY3023414 2Erlotinib Hydrochloride 2entinostat 1cediranib 1carboxyamido-triazole 1Thiotepa 1Thalidomide 1Temozolomide 1Sirolimus 1Radiotherapy, Image-Guided 1Pharmacogenomic Variants 1Peripheral Blood Stem Cell Transplantation 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ependymoma × cediranib × Genitourinary × Clear all
NCT01131234 2014-12-23

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
20 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Astrocytoma, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Ependymoma, Glioblastoma, Glioma, Melanoma, Oligodendroglioma, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Gliosarcoma, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡